0001415889-24-018375.txt : 20240627 0001415889-24-018375.hdr.sgml : 20240627 20240627200009 ACCESSION NUMBER: 0001415889-24-018375 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240626 FILED AS OF DATE: 20240627 DATE AS OF CHANGE: 20240627 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Reumuth Mary CENTRAL INDEX KEY: 0001710969 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38150 FILM NUMBER: 241080993 MAIL ADDRESS: STREET 1: 100 BEAVER STREET STREET 2: SUITE 201 CITY: WALTHAM STATE: MA ZIP: 02453 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: KALA BIO, Inc. CENTRAL INDEX KEY: 0001479419 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 270604595 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1167 MASSACHUSETTS AVENUE CITY: ARLINGTON STATE: MA ZIP: 02476 BUSINESS PHONE: 781-996-5252 MAIL ADDRESS: STREET 1: 1167 MASSACHUSETTS AVENUE CITY: ARLINGTON STATE: MA ZIP: 02476 FORMER COMPANY: FORMER CONFORMED NAME: Kala Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20091223 4 1 form4-06272024_080606.xml X0508 4 2024-06-26 0001479419 KALA BIO, Inc. KALA 0001710969 Reumuth Mary C/O KALA BIO, INC. 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 false true false false CHIEF FINANCIAL OFFICER 0 Common Stock 2024-06-26 4 S 0 4163 4.75 D 60187 D This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on June 22, 2023. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $5.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Includes 44,131 unvested RSUs. /s/ Mary Reumuth 2024-06-27